African Health Sciences 2013; 13(2): 219 - 232 http://dx.doi.org/10.4314/ahs.v13i2.4
Отчет по теме "производства опия в Афганистане в 2011 году".
The Story of Cholera was produced in collaboration with award-winning animator Yoni Goodman.
This animation covers cholera transmission, prevention, signs, and care in a simple and accessible way. The film follows evidence-based guidelines, has been field-tested, and reviewed for accuracy and conte...nt. Download flashcards and mobil phone versions from the website
more
MENSAJES DE AGUA, SANEAMIENTO e higiene EN ESTABLECIMIENTOS DE SALUD
Las medidas recomendadas existentes de agua, saneamiento e higiene en
entornos de atención médica son importantes para proporcionar una atención
adecuada a los pacientes y proteger a los pacientes y al personal considerando: ...la
provisión suficiente de agua potable segura para el personal, los cuidadores y los
pacientes; la higiene personal; la lavandería y la limpieza; los inodoros adecuados
y accesibles; manejo seguro de las excretas, que incluye mantener las excretas
(heces y orina) separadas del contacto humano y el tratamiento y eliminación
seguros en el medio ambiente; higiene frecuente de las manos utilizando la
técnica adecuada; limpieza y desinfección periódicas; y gestión segura de los
desechos de atención médica.
more
This article is part four in a series of explainers on vaccine development and distribution
Available in different languages
This article is part two in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. This article focuses on the ingredients in a vaccine and the three clinical trial phases. Part three outlines the nex...t part of the vaccine journey: the steps from completing the clinical trial phases through to distribution
Available in English, French, Spanish, Arabic, Chinese and Russian
more
La presente investigación se realizó con el objetivo de generar información que permita conocer los efectos que la pandemia por COVID-19 producen sobre el estado de salud mental y cambios en el comportamiento de niñas, niños y adolescentes, y presentar recomendaciones que orienten las acciones ...de diferentes actores relevantes, para evitar el sufrimiento y proteger la salud mental de niñas, niños y adolescentes.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Cum să faci ceea ce contează în perioade stresante este un ghid al OMS de gestionare a stresului, pentru a face faţă mai ușor greutăţilor. Acest ghid ilustrat vine în sprijinul implementării recomandărilor OMS pentru gestionarea stresului.